
MOLECULAR PARTNERS AG
Share · CH0256379097 · A12DEH (XSWX)
3,21 CHF
10.06.2025 08:05
Current Prices from MOLECULAR PARTNERS AG
Exchange | Ticker | Currency | Last Trade | Price | Daily Change |
---|---|---|---|---|---|
![]() London |
0QXX.L
|
CHF
|
10.06.2025 08:05
|
3,21 CHF
| 2,99 CHF
+7,54 %
|
Performance
Day | Week | Month | 3 Months | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|---|
0,00 % | 6,82 % | -6,82 % | -15,86 % | -35,41 % | -51,80 % | -51,80 % |
Company Profile for MOLECULAR PARTNERS AG Share
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Company Data
Name MOLECULAR PARTNERS AG
Company Molecular Partners AG
Primary Exchange
SIX
WKN A12DEH
ISIN CH0256379097
Asset Class Share
Sector Healthcare
Industry Medical - Pharmaceuticals
CEO Dr. Patrick Amstutz Ph.D.
Market Capitalization 132 Mio
Country Switzerland
Currency CHF
Employees 0,2 T
Address Wagistrasse 14, 8952 Schlieren
IPO Date 2014-11-05
Ticker Symbols
Name | Symbol |
---|---|
Frankfurt | 6ML.F |
London | 0QXX.L |
More Shares
Investors who MOLECULAR PARTNERS AG hold also have the following shares in their portfolio:
The financial platform MoneyPeak tracks and analyzes investments and portfolios.
From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.